761 related articles for article (PubMed ID: 30455077)
1. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
Matthay MA; Calfee CS; Zhuo H; Thompson BT; Wilson JG; Levitt JE; Rogers AJ; Gotts JE; Wiener-Kronish JP; Bajwa EK; Donahoe MP; McVerry BJ; Ortiz LA; Exline M; Christman JW; Abbott J; Delucchi KL; Caballero L; McMillan M; McKenna DH; Liu KD
Lancet Respir Med; 2019 Feb; 7(2):154-162. PubMed ID: 30455077
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.
Wilson JG; Liu KD; Zhuo H; Caballero L; McMillan M; Fang X; Cosgrove K; Vojnik R; Calfee CS; Lee JW; Rogers AJ; Levitt J; Wiener-Kronish J; Bajwa EK; Leavitt A; McKenna D; Thompson BT; Matthay MA
Lancet Respir Med; 2015 Jan; 3(1):24-32. PubMed ID: 25529339
[TBL] [Abstract][Full Text] [Related]
3. Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial.
Constantin JM; Jabaudon M; Lefrant JY; Jaber S; Quenot JP; Langeron O; Ferrandière M; Grelon F; Seguin P; Ichai C; Veber B; Souweine B; Uberti T; Lasocki S; Legay F; Leone M; Eisenmann N; Dahyot-Fizelier C; Dupont H; Asehnoune K; Sossou A; Chanques G; Muller L; Bazin JE; Monsel A; Borao L; Garcier JM; Rouby JJ; Pereira B; Futier E;
Lancet Respir Med; 2019 Oct; 7(10):870-880. PubMed ID: 31399381
[TBL] [Abstract][Full Text] [Related]
4. Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
Dixon B; Smith RJ; Campbell DJ; Moran JL; Doig GS; Rechnitzer T; MacIsaac CM; Simpson N; van Haren FMP; Ghosh AN; Gupta S; Broadfield EJC; Crozier TME; French C; Santamaria JD;
Lancet Respir Med; 2021 Apr; 9(4):360-372. PubMed ID: 33493448
[TBL] [Abstract][Full Text] [Related]
5. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.
Monsel A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Nguekap Tchoumba O; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Malard-Castagnet S; Burrel S; Rosenzwajg M; Tchitchek N; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Ropers J; Menasché P; Larghero J;
Crit Care; 2022 Feb; 26(1):48. PubMed ID: 35189925
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
7. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.
Villar J; Ferrando C; Martínez D; Ambrós A; Muñoz T; Soler JA; Aguilar G; Alba F; González-Higueras E; Conesa LA; Martín-Rodríguez C; Díaz-Domínguez FJ; Serna-Grande P; Rivas R; Ferreres J; Belda J; Capilla L; Tallet A; Añón JM; Fernández RL; González-Martín JM;
Lancet Respir Med; 2020 Mar; 8(3):267-276. PubMed ID: 32043986
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
Uccelli A; Laroni A; Ali R; Battaglia MA; Blinkenberg M; Brundin L; Clanet M; Fernandez O; Marriot J; Muraro P; Nabavi SM; Oliveri RS; Radue E; Ramo Tello C; Schiavetti I; Sellner J; Sorensen PS; Sormani MP; Wuerfel JT; Freedman MS;
Lancet Neurol; 2021 Nov; 20(11):917-929. PubMed ID: 34687636
[TBL] [Abstract][Full Text] [Related]
9. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group.
Abraham E; Baughman R; Fletcher E; Heard S; Lamberti J; Levy H; Nelson L; Rumbak M; Steingrub J; Taylor J; Park YC; Hynds JM; Freitag J
Crit Care Med; 1999 Aug; 27(8):1478-85. PubMed ID: 10470753
[TBL] [Abstract][Full Text] [Related]
10. Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome.
Gates S; Perkins GD; Lamb SE; Kelly C; Thickett DR; Young JD; McAuley DF; Snaith C; McCabe C; Hulme CT; Gao Smith F
Health Technol Assess; 2013 Sep; 17(38):v-vi, 1-87. PubMed ID: 24028755
[TBL] [Abstract][Full Text] [Related]
11. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Lanzoni G; Linetsky E; Correa D; Messinger Cayetano S; Alvarez RA; Kouroupis D; Alvarez Gil A; Poggioli R; Ruiz P; Marttos AC; Hirani K; Bell CA; Kusack H; Rafkin L; Baidal D; Pastewski A; Gawri K; Leñero C; Mantero AMA; Metalonis SW; Wang X; Roque L; Masters B; Kenyon NS; Ginzburg E; Xu X; Tan J; Caplan AI; Glassberg MK; Alejandro R; Ricordi C
Stem Cells Transl Med; 2021 May; 10(5):660-673. PubMed ID: 33400390
[TBL] [Abstract][Full Text] [Related]
12. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial.
Beigel JH; Aga E; Elie-Turenne MC; Cho J; Tebas P; Clark CL; Metcalf JP; Ozment C; Raviprakash K; Beeler J; Holley HP; Warner S; Chorley C; Lane HC; Hughes MD; Davey RT;
Lancet Respir Med; 2019 Nov; 7(11):941-950. PubMed ID: 31582360
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of acute respiratory distress syndrome (ARDS) in elderly patients.
Eachempati SR; Hydo LJ; Shou J; Barie PS
J Trauma; 2007 Aug; 63(2):344-50. PubMed ID: 17693834
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.
Zheng G; Huang L; Tong H; Shu Q; Hu Y; Ge M; Deng K; Zhang L; Zou B; Cheng B; Xu J
Respir Res; 2014 Apr; 15(1):39. PubMed ID: 24708472
[TBL] [Abstract][Full Text] [Related]
15. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial.
McAuley DF; Cross LM; Hamid U; Gardner E; Elborn JS; Cullen KM; Dushianthan A; Grocott MP; Matthay MA; O'Kane CM
Lancet Respir Med; 2017 Jun; 5(6):484-491. PubMed ID: 28526233
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stromal cells reduce evidence of lung injury in patients with ARDS.
Wick KD; Leligdowicz A; Zhuo H; Ware LB; Matthay MA
JCI Insight; 2021 Jun; 6(12):. PubMed ID: 33974564
[TBL] [Abstract][Full Text] [Related]
17. Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19: A Randomized, Placebo-Controlled Dosing Clinical Trial.
Lightner AL; Sengupta V; Qian S; Ransom JT; Suzuki S; Park DJ; Melson TI; Williams BP; Walsh JJ; Awili M
Chest; 2023 Dec; 164(6):1444-1453. PubMed ID: 37356708
[TBL] [Abstract][Full Text] [Related]
18. Best evidence in critical care medicine: The role of neuromuscular blocking drugs in early severe acute respiratory distress syndrome.
Needham CJ; Brindley PG
Can J Anaesth; 2012 Jan; 59(1):105-8. PubMed ID: 22042702
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Wharton Jelly Mesenchymal Stromal Cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial.
Pochon C; Laroye C; Kimmoun A; Reppel L; Dhuyser A; Rousseau H; Gauthier M; Petitpain N; Chabot JF; Valentin S; de Carvalho Bittencourt M; Peres M; Aarnink A; Decot V; Bensoussan D; Gibot S
Front Med (Lausanne); 2023; 10():1224865. PubMed ID: 37706025
[TBL] [Abstract][Full Text] [Related]
20. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial.
Tongyoo S; Permpikul C; Mongkolpun W; Vattanavanit V; Udompanturak S; Kocak M; Meduri GU
Crit Care; 2016 Oct; 20(1):329. PubMed ID: 27741949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
